KEY MESSAGE: Global Cancer Technology reports compelling synergy between its proprietary PI3K inhibitor GCT-007 and immune checkpoint therapies in preclinical models of childhood diffuse midline glioma (DMG).
San Diego, CA – November 1, 2025 – Global Cancer Technology (GCT) has announced new preclinical results that reveal powerful synergy between its proprietary PI3K inhibitor, GCT-007, and immune checkpoint inhibitors (ICIs) in treating Diffuse Midline Glioma (DMG). This rare and aggressive childhood brain cancer currently has very few effective options. The latest data will be featured at the upcoming Society for Neuro-Oncology (SNO) conference.
The research, led by Dr. Matt Dun and his team at the University of Newcastle (Australia), highlights the potential of this dual approach. Dr. Dun said,
“We have been consistently impressed by the activity of GCT-007 in our combination studies and look forward to conducting additional research using this promising agent.”
His statement reinforces how GCT-007 strengthens immune-based treatments in preclinical settings. Dr. Karen Newell Rogers, Chief Scientific Advisor at GCT, emphasized the growing promise of this therapy.
“We continue to accumulate compelling evidence of GCT-007’s potential in treating this devastating childhood brain cancer as a combination therapy,” she said. “These results strongly support further preclinical investigation of GCT-007 in combination approaches for DMG patients.”
John Clark, CEO of Global Cancer Technology, added:
“The growing body of preclinical data demonstrating GCT-007’s efficacy is highly encouraging. Collaborating with Dr. Dun and her team at the University of Newcastle remains a key focus of our research efforts.”
Together, these insights demonstrate that GCT’s collaborative approach is yielding measurable progress.
Why This Matters
DMG remains one of the most lethal pediatric brain cancers. Few effective treatment options exist and the prognosis is extremely poor. Recent advances in understanding the tumor’s molecular biology and microenvironment underscore the importance of novel approaches, including targeted inhibition of pathways such as PI3K/mTOR and immunotherapy [source]. By combining a PI3K inhibitor with immune checkpoint therapy, GCT is attacking the tumor from two directions:
-
It disrupts key signaling pathways that drive tumor growth.
-
It activates the immune system to recognize and destroy cancer cells.
This dual-action strategy may help overcome two long-standing challenges: the tumor’s aggressive biology and its “immune-cold” environment [source]. As research continues, the synergy between these approaches could open new treatment pathways for children diagnosed with this devastating disease.
Next Steps
GCT will expand its preclinical studies to refine dosage and timing strategies for GCT-007 plus ICIs. The company will also pursue additional collaborations to accelerate translational development. Its ongoing partnership with the University of Newcastle remains central to these efforts. Through this partnership, GCT aims to advance a treatment strategy that may one day improve survival and quality of life for young DMG patients.
Forward-Looking Statements
This news release contains forward-looking statements under Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934. These statements involve risks and uncertainties, including the possibility that GCT’s products may not receive FDA clearance or achieve commercialization success. Readers should review the company’s latest shareholder communications for additional information.
Summary
The new data reinforce GCT’s leadership in pediatric neuro-oncology innovation. By pairing GCT-007 with immune checkpoint inhibitors, the company is forging a science-based path toward more effective combination therapies for Diffuse Midline Glioma.
Ongoing studies will continue to define how this synergy could reshape the treatment landscape for children with DMG.
